Font Size: a A A
Keyword [BCRP]
Result: 81 - 100 | Page: 5 of 6
81. UGT Metabolism Of Esculetin And Methylesculetin
82. Interactions And Compatibility Mechanism Of The Major Effective Components In Shengmai Formula Mediated By BCRP At The Cellular And Vesicular Levels
83. Impact Of Inflammatory Cytokine IL-1β On The Expression Of Multiple Drug Resistance Protein BCRP/ABCG2 In Synoviocytes Of Patients With Rheumatoid Arthritis
84. Epithelial Cell Adhesion Molecule (EpCAM) Promotes Resistance And Stemness Of Breast Cancer Cells By Inducing EMT
85. Curcumin Enhances The Sensitivity Of Hepatocellular Carcinoma Cells To Sorafenib By Inhibiting The PI3K/AKT Pathway
86. Effects And Molecular Mechanism Of PLOD2 On 5-FU Resistance In Gastric Cancer Cells
87. Active efflux transport and CNS distribution of the novel antifolate pemetrexed
88. Identification and characterization of tissue-specific alternative promoter usage for Bcrp1/Abcg2 in mice for establishing a murine in vivo model of dietary transcriptional regulation of human small intestinal Bcrp/Abcg2 expression
89. Interaction of rotenone and its metabolites with P-gp, BCRP, and MRP-2 efflux transporters
90. Targeted delivery of anti-retroviral nucleosides: Role of breast cancer resistance protein
91. Transporter-mediated flavonoid-drug interactions: In vitro and in vivo
92. Modulation of efflux transporters by flavonoids: Drug interactions and MDR reversal
93. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as multidrug resistance inhibitors
94. Dietary organic isothiocyanates as modulators of ATP-binding cassette transporters
95. Characterizing the transport and disposition of resveratrol and its metabolites in the presence of MRP2, BCRP and enterohepatic circulation inhibitors
96. Overcoming multidrug resistance
97. Multidrug transporters: A study of drug interactions using a photoactive analogue of Rhodamine 123
98. Improving delivery of elacridar to enhance efficacy of molecularly-targeted agents in treatment of glioblastoma
99. Preclinical pharmacology of the MDM2 antagonist nutlin-3a
100. Nilotinib (TasignaRTM) Modulates ABCB1/PGP- and ABCG2/BCRP-mediated multidrug resistance in cancer chemotherapy
  <<First  <Prev  Next>  Last>>  Jump to